NFKB1 and glioblastoma: Recent studies indicated a substantial role of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling in GBM, highlighting NF-κB activation as a critical element contributing to the malignancy linked to poor prognoses in GBM patients [16].